Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Epilepsy and seizure classification

Efficacy and safety of VNS therapy or continued medication management for treatment of adults with drug-resistant epilepsy: systematic review and meta-analysis.

Sarah Batson; Rohit Shankar; Joan Conry; Jane Boggs; Rodney Radtke; Stephen Mitchell; Francesca Barion; Joanna Murphy; Vanessa Danielson

Originally published in Journal of neurology · 2022-01-16

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Vagus nerve stimulation (VNS) Therapy® is an adjunctive neurostimulation treatment for people with drug-resistant epilepsy (DRE) who are unwilling to undergo resective surgery, have had unsuccessful surgery or are unsuitable for surgery. A systematic review and meta-analysis were conducted to determine the treatment effects of VNS Therapy as an adjunct to anti-seizure medications (ASMs) for the management of adults with DRE. A literature search was performed in August 2020 of the Medline®, Medline® Epub Ahead of Print, Embase, and the Cochrane library databases. Outcomes examined included reduction in seizure frequency, seizure freedom, ASM load, discontinuations, and serious adverse events (SAEs). Comparators included best medical practice, ASMs, low-stimulation or sham VNS Therapy. Four RCTs and six comparative observational studies were identified for inclusion.

Discussion

This systematic review and meta-analysis demonstrated that in people with DRE, adjunctive high-stimulation VNS Therapy resulted in statistically significant reductions in seizure frequency without increasing the rate of SAEs or discontinuations when compared with adjunctive low-stimulation VNS Therapy/ASM/best medical practice. This evidence validates the consideration of VNS Therapy for people who respond poorly to ASMs, or those who are unsuitable for or unwilling to undergo any cranial procedure.

Conclusions

Although there is much literature devoted to VNS Therapy, there is a paucity of comparative data and this should be a focus for future research. This meta-analysis demonstrated the benefits of VNS Therapy in people with DRE, which included improvement in seizure frequency without an increase in the rate of SAEs or discontinuations. The evidence validates the consideration of VNS Therapy for people who are not responding to ASMs, or those who are unsuitable for or unwilling to undergo cranial procedures.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?